Enlarge / On May 22, John Timmer (left) moderated a panel featuring Karin Bok (center) and Nathaniel Wang (right) for the Ars Frontiers 2023 session titled, "Beyond COVID: What Does mRNA Technology Mean for Disease Treatment?" (credit: Ars Technica)

The world of biomedicine has developed a lot of technology that seems a small step removed from science fiction, but the public isn't aware of much of it. mRNA-based vaccines, though, were a big exception as a lot of the public tracked the technology's development as a key step toward emerging from the worst of the pandemic and then received the vaccines in droves.

mRNA technology has a lot of potential applications beyond COVID, and we talked a bit about those during the "Beyond COVID: What Does mRNA Technology Mean for Disease Treatment?" panel at last week's Ars Frontiers event. We've archived the panel on YouTube; if you want to focus on the discussion about mRNA therapies, you can start at the 1-hour, 55-minute mark .

mRNA is a nucleic acid molecule that instructs the cell to make specific proteins. When used as vaccines, the instructions call for a protein produced by a pathogen, such as a virus. "It helps put up a wanted poster for the immune system," was how Nathaniel Wang, co-founder and CEO of Replicate Bioscience put it.

Enlarge / On May 22, Benj Edwards (left) moderated a panel featuring Paige Bailey (center), Haiyan Zhang (right) for the Ars Frontiers 2023 session titled, "The Lightning Onset of AI — What Suddenly Changed?" (credit: Ars Technica)

On Monday, Ars Technica hosted our Ars Frontiers virtual conference. In our fifth panel, we covered "The Lightning Onset of AI—What Suddenly Changed?" The panel featured a conversation with Paige Bailey , lead product manager for Generative Models at Google DeepMind, and Haiyan Zhang , general manager of Gaming AI at Xbox, moderated by Ars Technica's AI reporter, Benj Edwards .

The panel originally streamed live, and you can now watch a recording of the entire event on YouTube. The "Lightning AI" part introduction begins at the 2:26:05 mark in the broadcast.

With "AI" being a nebulous term, meaning different things in different contexts, we began the discussion by considering the definition of AI and what it means to the panelists. Bailey said, "I like to think of AI as helping derive patterns from data and use it to predict insights ... it's not anything more than just deriving insights from data and using it to make predictions and to make even more useful information."

It's Frontiers Day at Ars Technica! Between the hours of 13:30 and 17:00 (all times US Eastern Daylight, UTC-4:00), we'll be carrying our livestreamed discussion with a half-dozen expert-packed panels on topics that range from IT to health care to space innovation. Each session will last approximately 30 minutes, with the last 10 minutes reserved for questions and answers from the audience. If you want to weigh in, leave your questions as comments on the YouTube stream . (You can also leave questions in the comments of this article, but YouTube is the preferred place because the moderators gathering questions will be focusing their efforts there.)

Schedule and sessions

The event kicks off at 13:30 EDT, with a quick intro from Ars Editor-in-Chief Ken Fisher and me. Even though this is a virtual event, Ken and I will be at the Ars studio at the Condé Nast Manhattan office to act as hosts. Ken will welcome everyone in and say some opening remarks, and we'll roll from there directly into the sessions. Each session will also be bookended by a short recap by Ken and me.

Session 1: TikTok—banned or not, it's probably here to stay (13:30 EDT)

Ars senior policy reporter Ashley Belanger gets to be up first with an especially relevant topic : While Congress and various states are vowing action against TikTok, will "banning" the app (whatever "banning" actually means) really come to anything? What are the policy implications around this kind of regulation, and how did we get here? We'll feature EFF Legal Director Corynne McSherry among the panel's guests, along with Columbia University's Ioana Literat and former White House lawyer and CPRI Executive Director Bryan Cunningham .